Anti–interleukin five (IL-5) biologics such as mepolizumab and benralizumab have shown significant efficacy in reducing ...

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

Swiss gene-editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and San Diego, USA-based Sirius Therapeutics, which is ...

German drugmaker Boehringer Ingelheim has released full Phase III results for its experimental lung disease drug ...

Marking International Clinical Trials Day, we bring you a special Q&A with Andrea Manfrin, Deputy Director of Clinical Trials ...

Formycon and its commercialization partner Fresenius Kabi have announced that the US Food and Drug Administration (FDA) has ...

Genetic medicines company Arbor Biotechnologies has announced the appointment of Don Haut as chief business officer.

The USA’s Institute for Clinical and Economic Review (ICER) has posted a Protocol today outlining how it will conduct a new ...

US human genetics biotech 23andMe (OTC: MEHCQ) today revealed it has entered into a definitive agreement for the sale of the ...

Cambridge, UK-based CellCentric today announced the completion of a $120 million Series C funding round. The clinical-stage ...

Major progress has been made in delivering a more efficient and adaptable regulatory framework for clinical trials, and Lawrence Tallon, chief executive of the UK’s Medicines and Healthcare products ...

USA-based rare disease company Applied Therapeutics (Nasdaq: APLT) saw its shares rise nearly 23% to $0.60 on Friday, ahead ...